AMGN Amgen Corp Earnings per share for the last twelve months

Corporate company logo of Amgen Inc (AMGN)

High R&D costs and FDA oversight create significant barriers to entry, allowing Amgen Inc. (AMGN) to dictate premium pricing for unique biologics. The fundamental TTM net income per share metric in the price action on the GURU.Markets chart confirms this strategy, where the 17.37 mark reflects the current state. A stable staff of leading geneticists guarantees further growth in pipeline efficiency.

AMGN (Amgen Inc) Earnings per share for the last 12 months history from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for Amgen Corporation (AMGN)

- current quotes and average value forecast:
Price Chart Amgen Inc|AMGN - Average Forecast Price
- market capitalization data:
Market Value Amgen Corporation|AMGN - Total Company Value
- shareholders' equity book value data:
Book Value per Share Amgen|AMGN - Accounting Capitalization|Market Capitalization to Book Value Ratio amgen.com|AMGN - Company Total Asset Base
- company total debt and liquidity indicators:
Debt to Equity Amgen Inc.|AMGN - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Amgen Inc|AMGN - Company Total Indebtedness|Debts to Book Capitalization Amgen Corp|AMGN - Company Long-Term Debts|Company Short-Term Debt Amgen|Quick Ratio amgen.com
- net income and valuation multiples indicators:
AMGN - Annual Net Income|Projected Future Earnings Amgen Inc.|AMGN - Market Cap to Earnings|Future Price to Earnings Amgen Inc.|AMGN - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Amgen Inc|AMGN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Amgen|AMGN - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months amgen.com|AMGN - Earnings per share growth this year|Earnings growth forecast for next year Amgen Inc.
- sales volume and revenue information:
AMGN - Company Sales|Company Future Sales Volume Amgen Corp|AMGN - Price-to-Revenue Coefficient|Forward P/S Multiple Amgen Corp
Comprehensive company analysis:amgen.com (AMGN)
Mass-produced product of Amgen Corp

Amgen Inc. effective management of M&A and patent protection translates directly into sustainable profitability, as reflected by the trailing 12-month earnings per share. This indicator is calculated by dividing the total annual net income by the number of shares outstanding, allowing investors to assess the asset's real yield without issuance noise and avoid overpaying for an overheated stock.

Competitors of Amgen Inc. (AMGN)

LLY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months AbbVie Inc|AZN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NVS|MRK (merck.com) - Net earnings per share (EPS TTM)|novonordisk.com (NVO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pfizer Corporation (PFE)|Sanofi S.A. - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) BMY (Bristol Myers Squibb Company)|Net earnings per share for the trailing year GSK Corp|TAK: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Teva Pharmaceuticals (TEVA)|Dr. Reddy's (RDY) - Earnings per share for the last twelve months|VTRS (Viatris) - Earnings per share for the last twelve months|Earnings per share for the last twelve months roivant.com|Net earnings per share (EPS TTM) Zai Lab Ltd.|Earnings per share for the last twelve months bauschhealth.com (BHC)|Net earnings per share for the last four quarters cosmosholdingsinc.com